Skip to main content

First Trust NYSE Arca Biotechnology Index Fund (FBT)

NYSEARCA: FBT · IEX Real-Time Price · USD
165.51 1.45 (0.88%)
Oct 25, 2021 4:00 PM EDT - Market closed
Assets$1.79B
NAV$164.09
Expense Ratio0.55%
PE Ratio29.63
Shares Out10.90M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateSep 23, 2015
1-Year Return
-
Volume26,430
Open164.09
Previous Close164.06
Day's Range163.67 - 165.71
52-Week Low150.33
52-Week High186.51
Beta0.98
Holdings31
Inception DateJun 19, 2006

About FBT

The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.

Asset ClassEquity
SectorBiotech
RegionGlobal
IssuerFirst Trust Portfolios
Stock ExchangeNYSEARCA
Ticker SymbolFBT
Index TrackedNYSE Arca Biotechnology Index

Top 10 Holdings

34.87% of assets
NameSymbolWeight
BioNTech SEBNTX3.76%
ACADIA PharmaceuticalsACAD3.54%
Agios PharmaceuticalsAGIO3.51%
QiagenQGEN3.49%
Charles River LaboratoriesCRL3.48%
Regeneron PharmaceuticalsREGN3.46%
IQVIA HoldingsIQV3.45%
United TherapeuticsUTHR3.41%
Bio-TechneTECH3.39%
Vertex PharmaceuticalsVRTX3.37%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Sep 23, 2015$0.0197Sep 30, 2015
Jun 24, 2015$0.0649Jun 30, 2015
Mar 25, 2015$0.0476Mar 31, 2015
Dec 23, 2014$0.0524Dec 31, 2014
Full Dividend History

News

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Smart Beta ETF report for FBT

1 day ago - Zacks Investment Research

Can Biotech ETFs Gain From Positive Booster Update?

In an effort to combat the coronavirus outbreak and accelerate the distribution process of extra doses in the United States, the FDA has approved the vaccine booster shots.

Other symbols:BBHBTECIBBXBI
4 days ago - Zacks Investment Research

Biotech ETFs to Benefit From Latest Booster Update

The U.S. government's plans to make COVID-19 vaccine booster shots available from next month will likely increase the profits of vaccine makers.

2 months ago - Zacks Investment Research

Delta Variant Surge Brings Biotech ETFs in Focus

The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.

2 months ago - Zacks Investment Research

Top-Performing Biotech ETFs of Last Week

Investors may want to tap the bullishness in the sector with the best biotech ETFs of last week.

4 months ago - Zacks Investment Research

Will Biotech ETFs Benefit from Biogen's New Alzheimer's Drug?

Biotech investors may have reason to celebrate this week, as the FDA approved Biogen's Alzheimer's disease drug Aducanumab on Monday, ushering in the first medication to be allowed by U.S. regulators to...

Other symbols:BBHPBE
4 months ago - ETF Trends

5 Top ETFs With Exposure To Biogen

For the first time in 18 years, there was a new treatment for Alzheimer's Disease approved by the FDA. Aducanumab from Biogen Inc (NASDAQ: BIIB) was approved as a drug that can reduce the clinical decli...

Other symbols:BIIBBBHIBBPBEPKW
4 months ago - Benzinga

Top COVID-19 Vaccine Stories of May Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of May and the possible impact they can have on biotech ETFs.

4 months ago - Zacks Investment Research

Biotech ETFs to Suffer as US Backs IP Waiver for COVID-19 Vaccines

The Biden administration recently informed about supporting the waiver of intellectual property protections for COVID-19 vaccines that has been proposed by South Africa and India.

5 months ago - Zacks Investment Research

Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus

Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.

5 months ago - Zacks Investment Research

Top COVID-19 Vaccine Stories of March Put Biotech ETFs in Focus

Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence with multiple mutants.

6 months ago - Zacks Investment Research

A Guide to Biotech ETF Investing Amid the Coronavirus Crisis

The biotech space had an impressive run on the bourses in 2020 as the coronavirus pandemic triggered a race to roll out vaccine and treatment.

9 months ago - Zacks Investment Research

ETF Market Outlook & Picks for 2021

Two ETF experts share their market outlook and top picks for 2021.

9 months ago - Zacks Investment Research

ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion

AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.

Other symbols:BBHPBEPJPPPH
10 months ago - Zacks Investment Research

3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover

The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a $39-billion takeover of Alexion ...

Other symbols:BBHPBE
10 months ago - Benzinga

ETF Sectors to Bet on Positive Vaccine News

The introduction of the coronavirus vaccine is expected to help in the economic recovery, especially for sectors which have taken a hit from the social-distancing and lockdown measures.

11 months ago - Zacks Investment Research

Can't Get Enough Biotech Exposure in Your Portfolio?

As coronavirus cases start to tick upwards once more, the race to create a vaccine will only intensify, boding well for the biotechnology sector. ETF investors may want to keep an eye on biotech funds, ...

Other symbols:ARKGBBHXBI
11 months ago - ETF Trends

7 Biotech Stocks To Buy For Profit From The Vaccine Crunch

As the race to develop a vaccine continues, these biotech stocks could be high risk, high return propositions. The post 7 Biotech Stocks To Buy For Profit From The Vaccine Crunch appeared first on Inves...

Other symbols:GILDGERMPFEREGNWST
1 year ago - InvestorPlace

Biotech ETFs in Focus as the COVID-19 Vaccine Race Intensifies

Johnson & Johnson's entry into the late-stage trials has increased optimism in the coronavirus vaccine development.

Other symbols:ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

3 Healthcare ETFs to Buy for Health and Safety

Not all healthcare ETFs are the same and as this group of three proves, that can be a positive for savvy investors. The post 3 Healthcare ETFs to Buy for Health and Safety appeared first on InvestorPlace.

Other symbols:EDOCTDOC
1 year ago - InvestorPlace

Encouraging Election Year History for this Biotech ETF

Healthcare is one of the most politically sensitive sectors and that sensitivity is on full display in recent weeks with biotechnology ETFs, including the First Trust NYSE Arca Biotechnology Index Fund ...

1 year ago - ETF Trends

How Will Biotech ETFs React to Vaccine Makers' Safety Pledge?

Nine vaccine developers have jointly pledged to observe high ethical standards in conducting clinical studies and manufacturing of vaccines.

Other symbols:ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

Election History Says Buy Biotech Dip

Biotechnology exchange-traded funds were hot until they weren't. History indicates recent weakness in the previously high-flying group be a symptom of election year jitters and investors shouldn't ignor...

1 year ago - Benzinga

Biotech ETFs to Shine Bright on Coronavirus Vaccine Progress

AstraZeneca's initiation of a phase III study has heated up competition to bring a coronavirus vaccine to the markets.

Other symbols:ARKGBBHIBBXBI
1 year ago - Zacks Investment Research

Post-Pandemic Stars Could Align For This Biotech ETF

These days, it's not hard to find winners among health care exchange-traded funds and that's true of both established and rookie players.

1 year ago - Benzinga